Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:2 Issue:11 Number:55 ISSN#:2564-2537
Author Verified
ACE Report #4726
Ace Report Cover Tumour

Zoledronic acid reduces number of skeletal-related events in new multiple myeloma patients

How to Cite

OrthoEvidence. Zoledronic acid reduces number of skeletal-related events in new multiple myeloma patients. ACE Report. 2013;2(11):55. Available from: https://myorthoevidence.com/AceReport/Report/4726

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial

Lancet Oncol. 2011 Aug;12(8):743-52. doi: 10.1016/S1470-2045(11)70157-7. Epub 2011 Jul 21

Contributing Authors: GJ Morgan JA Child WM Gregory AJ Szubert K Cocks SE Bell N Navarro-Coy MT Drayson RG Owen S Feyler AJ Ashcroft FM Ross J Byrne H Roddie C Rudin G Cook GH Jackson P Wu FE Davies National Cancer Research Institute Haematological Oncology

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


1960 patients with multiple myeloma were randomized to undergo either intensive or non-intensive treatment. Within each treatment type patients were further randomized to receive either zoledronic acid intravenously or clodronic acid orally, in order to determine which bisphosphonate and treatment type was more effective in lowering the danger of skeletal-related events. Following assessments over...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

For Reprints and Permissions, click here

Please Login or Join to leave comments.